The study of combination cream of salicylic acid, aqua posae filiformis, niacinamide, lipohydroxy acid, procerad, and zinc PCA

illustrative image

Dr.dr.Irma Bernadette, SpKK (K) is starting a new clinical trial of Effectivity and Safety of Combination Cream of Salicylic Acid, Aqua Posae Filiformis, Niacinamide, Lipohydroxy Acid, Procerad, and Zinc PCA as adjuvant therapy for acne vulgaris patients.

These combination cream will be tested by mild to moderate acne vulgaris patients. Participants will be female patients aged 15-50 years old and divided into three groups. The control group (Group 1) will use Adapalene 0.1% cream only every night. Group 2 will use Adapalene 0.1% cream intermittently every two nights and the combination cream every morning. Group 3 will use Adapalene 0.1% cream every night and the combination cream every morning.

This study is an experimental study with a randomized controlled trial (RCT) design on mild to moderate acne vulgaris patients who met the inclusion criteria. The clinical trial started on August 1, 2022 and will continue throughout December 31, 2022.

Change of Level Of Seborrhea will be primary outcome measure. The level of seborrhea is assessed subjectively by participants on a scale of 0 (minimum level) - 10 (maximum level).

For more details: https://ichgcp.net/clinical-trials-registry/NCT05497323.

Clinical Research News

Upcoming Clinical Trials

3